Atrium Therapeutics Inc (RNA) FinancialsRNAAtrium Therapeutics Inc

Evaluating the bottom line, Atrium Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -88.01%, while the net margin is -84.71%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RNA converts its operational activities into shareholder value.

In the context of the broader market, RNA competes directly with industry leaders such as GLSI and CGEN. With a market capitalization of $219.64M, it holds a significant position in the sector. When comparing efficiency, RNA's gross margin of 100.00% stands against GLSI's N/A and CGEN's -3.54%. Such benchmarking helps identify whether Atrium Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Avidity has reported a gross margin of 100% consistently across recent quarters, indicating strong profitability on its revenue. However, it has also faced significant net losses, with a net income of -16,633,000 USD in the most recent quarter.